Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.
No takes yet. Share an insight, caveat, or question.
Kris et al. (2003) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: